用于检测肺癌风险的微小RNA生物标志物
MicroRNA Biomarker for Detecting the Risk of Lung Cancer.
作者信息
Li Lei, Feng Tienan, Zhang Weituo, Gao Sumeng, Wang Ruoyang, Lv Wenwen, Zhu Tengteng, Yu Herbert, Qian Biyun
机构信息
Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
Int J Genomics. 2020 Jan 2;2020:7415909. doi: 10.1155/2020/7415909. eCollection 2020.
BACKGROUND
Lung cancer is one of the leading diagnosed cancers worldwide, and microRNAs could be used as biomarkers to diagnose lung cancer. has been demonstrated to affect the prognosis of NSCLC (non-small-cell lung cancer) in a previous study. However, the diagnostic value of in lung cancer has not been investigated.
METHODS
To evaluate the ability of to diagnose lung cancer, we compared the expression of in lung cancer patients, COPD patients, and normal controls. Receiver operating characteristic (ROC) curve analysis was performed to investigate the sensitivity and specificity of . Coexpression network and pathway analysis were carried out to explore the mechanism.
RESULTS
We found that had lower expression in lung cancer and COPD patients than in normal controls, and the AUC was 0.92 for diagnosing lung cancer. correlated with , and by combining these two microRNAs, the AUC was 0.97 for diagnosing lung cancer.
CONCLUSIONS
may act as a biomarker that contributes to the diagnosis of lung cancer and the detection of its high-risk population.
背景
肺癌是全球诊断出的主要癌症之一，微小RNA可作为诊断肺癌的生物标志物。在先前的一项研究中已证明其会影响非小细胞肺癌（NSCLC）的预后。然而，其在肺癌中的诊断价值尚未得到研究。
方法
为评估其诊断肺癌的能力，我们比较了肺癌患者、慢性阻塞性肺疾病（COPD）患者和正常对照中该物质的表达情况。进行了受试者工作特征（ROC）曲线分析以研究其敏感性和特异性。开展了共表达网络和通路分析以探索其机制。
结果
我们发现该物质在肺癌患者和COPD患者中的表达低于正常对照，其诊断肺癌的曲线下面积（AUC）为0.92。其与另一种物质相关，通过联合这两种微小RNA，诊断肺癌的AUC为0.97。
结论
该物质可能作为一种生物标志物，有助于肺癌的诊断及其高危人群的检测。
Zotero 插件